Amarin (AMRN) vs Assembly Biosciences (ASMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Amarin (AMRN) has outperformed Assembly Biosciences (ASMB) over the past year, losing 35.5% versus a loss of 42.4%. Over five years, ASMB leads with a -21.3% price change compared with -85.5% for AMRN. Assembly Biosciences is the larger company by market cap ($454.4 million vs $444.4 million), about 1.0 times the size.
Assembly Biosciences converts more of its revenue into profit, with a net margin of -8.5% versus -18.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | ASMB |
|---|---|---|
| Share price | $10.57 | $22.19 |
| Market cap | $444.39M | $454.39M |
| 1-day change | -6.13% | -1.38% |
| YTD return | -24.28% | -34.75% |
| 1-year return | -35.47% | -42.36% |
| 5-year return | -85.48% | -21.31% |
| P/E ratio (TTM) | — | 29.59 |
| Forward P/E | 10.79 | — |
| EPS (TTM) | $-0.80 | $0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $213.65M | $72.30M |
| Revenue growth (YoY) | -6.55% | +153.52% |
| Net income (latest FY) | $-38.80M | $-6.12M |
| Gross margin | 56.57% | — |
| Operating margin | -23.48% | -16.76% |
| Net margin | -18.16% | -8.47% |
| 52-week high | $17.31 | $39.65 |
| 52-week low | $10.56 | $19.20 |
| Distance from 52-week high | -38.94% | -44.04% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +22.99% | +130.73% |
| Average volume | 79.50K | 309.38K |
| Shares outstanding | 42.04M | 20.48M |
| Employees | 80 | 73 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Assembly Biosciences is more profitable, keeping -8.5 cents of every revenue dollar as net income versus -18.2 cents for Amarin.
- Assembly Biosciences grew revenue faster in its latest fiscal year (+153.52% vs -6.55%).
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
AMRN vs ASMB FAQ
Which is bigger, Amarin or Assembly Biosciences?
Assembly Biosciences (ASMB) is larger, with a market capitalization of $454.39M compared with $444.39M for Amarin (AMRN).
Which stock has performed better over the past year, AMRN or ASMB?
AMRN returned -35.47% over the past 12 months, compared with -42.36% for ASMB (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and Assembly Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.